Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06212193 · ClinicalTrials.gov registry record · NA
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
A NA study of Tricuspid Regurgitation and Tricuspid Regurgitation Functional, sponsored by Innoventric.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 12
- Study locations
NCT06212193: Recruiting NA study of Tricuspid Regurgitation and Tricuspid Regurgitation Functional, sponsored by Innoventric.
NCT06212193 is a NA study of Tricuspid Regurgitation and Tricuspid Regurgitation Functional that is actively recruiting participants, run by Innoventric. The registered enrollment target is 15 participants, below the 535-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06212193, a NA study of Tricuspid Regurgitation and Tricuspid Regurgitation Functional, is actively recruiting participants, sponsored by Innoventric.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 12
- Study locations
Study Summary
Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).
Primary Outcome
Rate of device or procedure-related Major Adverse Events (MAEs) And Rate of unplanned surgery or re-intervention due to a life-threatening device or procedure failure
Conditions Studied
Interventions
- DEVICE Trillium™
Study Locations (12)
New York
- Weill Cornell Medicine - New York
- Stony Brook Heart Institute - Stony Brook
California
- Cardiovascular Institute of Los Robles Health System - Thousand Oaks
Michigan
- Ascension St. John - Detroit
Minnesota
- Mayo Clinic Hospital (Rochester) - Rochester
Ohio
- The Christ Hospital - Cincinnati
Pennsylvania
- Lankenau Heart Institute - Philadelphia
Tennessee
- TriStar Centennial Medical Center - Nashville
Washington
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2030-08 |
| Phase | NA |
What NCT06212193 shows while recruiting
NCT06212193 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 535-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Tricuspid Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Trillium™ is the first listed.
NCT06212193 lists 12 locations in 11 states (New York, California, Michigan).
Frequently Asked Questions
What is clinical trial NCT06212193 about?
NCT06212193 is a clinical study titled "Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)". Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).
What is the current status of trial NCT06212193?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-08-05. Estimated completion is 2030-08.
What conditions does trial NCT06212193 study?
This clinical trial studies the following conditions: Tricuspid Regurgitation, Tricuspid Regurgitation Functional.
What interventions are being tested in trial NCT06212193?
The interventions under investigation include: Trillium™ (DEVICE).
Who is sponsoring clinical trial NCT06212193?
This trial is sponsored by Innoventric, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06212193 being conducted?
This trial has 12 study locations across California, Michigan, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tricuspid Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06212193's enrollment target sits among peer trials
15 17th of 17 the lowest of 17 other Tricuspid Regurgitation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tricuspid Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TTVR Early Feasibility Study
RECRUITING · NA
-
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
RECRUITING · NA
-
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
RECRUITING · NA
-
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
RECRUITING · NA
-
Trisol System EFS Study
RECRUITING · NA
-
EFS of the DUO System for Tricuspid Regurgitation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI